Cepheid, a Danaher company, and Oxford Nanopore Technologies announced on April 15, 2026, that they are expanding their collaboration to develop a phase‑two workflow for rapid bacterial and fungal pathogen identification. The new phase builds on a successful phase‑one program that was highlighted at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2025 conference in Vienna.
The expanded workflow will combine Oxford Nanopore’s real‑time nanopore sequencing technology with Cepheid’s GeneXpert platform, creating a single, end‑to‑end solution that delivers genomic analysis in clinical laboratories. The goal is to provide clinicians with faster, more accurate pathogen identification and antimicrobial resistance profiling, potentially reducing diagnostic turnaround times from days to hours.
From a strategic perspective, the partnership strengthens Danaher’s position in the molecular diagnostics market by adding a high‑value, high‑margin genomic sequencing capability to its existing portfolio. The collaboration also positions both companies to capture a growing share of the personalized medicine and rapid diagnostics market, where demand for comprehensive, real‑time pathogen data is increasing.
"Phase two reflects our shared commitment to making advanced infectious disease research more practical and widely achievable," said Vitor Rocha, President of Cepheid. "By leveraging the scale and simplicity of Cepheid’s GeneXpert® platform together with Oxford Nanopore’s sequencing technology, we are increasing access to critical infectious disease information." "We are very encouraged by the success and early feedback from the first phase solution and are excited to broaden the workflow’s transformative possibilities to additional research labs," added Francis Van Parys, CEO of Oxford Nanopore.
The partnership faces typical integration challenges, including aligning two distinct technologies and navigating regulatory approval pathways for clinical diagnostics. However, the potential benefits—faster diagnostic turnaround, improved antimicrobial stewardship, and enhanced outbreak surveillance—represent significant opportunities for both companies to differentiate themselves in a highly competitive diagnostics landscape.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.